Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) CEO Timothy P. Noyes sold 10,000 shares of the business’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $24.70, for a total transaction of $247,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Timothy P. Noyes also recently made the following trade(s):
- On Monday, April 1st, Timothy P. Noyes sold 10,000 shares of Aerovate Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00.
Aerovate Therapeutics Trading Down 4.0 %
Shares of NASDAQ AVTE opened at $21.60 on Friday. The company has a market capitalization of $601.78 million, a price-to-earnings ratio of -7.50 and a beta of 1.23. The business has a 50 day simple moving average of $24.43 and a 200-day simple moving average of $19.08. Aerovate Therapeutics, Inc. has a twelve month low of $9.41 and a twelve month high of $32.42.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Several brokerages have commented on AVTE. Wells Fargo & Company restated an “overweight” rating and set a $35.00 price objective on shares of Aerovate Therapeutics in a research note on Monday, April 1st. Wedbush reiterated an “outperform” rating on shares of Aerovate Therapeutics in a research note on Thursday, April 4th. Finally, Jefferies Financial Group began coverage on shares of Aerovate Therapeutics in a research note on Monday, March 25th. They issued a “buy” rating and a $65.00 price target on the stock.
View Our Latest Stock Report on AVTE
About Aerovate Therapeutics
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Articles
- Five stocks we like better than Aerovate Therapeutics
- Breakout Stocks: What They Are and How to Identify Them
- Comprehensive PepsiCo Stock Analysis
- What is a SEC Filing?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What is Put Option Volume?
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.